Frankfurt - Delayed Quote EUR

Mendus AB (publ) (1YG0.F)

0.5720

+0.1180

+(25.99%)

At close: June 13 at 8:07:01 AM GMT+2

Mendus AB (FRA:1YG0) Q4 2024 Earnings Call Highlights: Strategic Advances Amidst Financial ...

Mendus AB (FRA:1YG0) extends its cash runway to 2026 while navigating clinical and market hurdles.

GuruFocus.com 3 months ago

1YG0.F
+25.99%
Edison Issues Report on Mendus (IMMU)

London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU)Mendus continues to make headway with its lead programme assessing cancer vaccine vididencel as a potential maintenance therapy for acute myeloid leukaemia (AML), with the latest update presented at the 66th annual American Society of Hematology (ASH) meeting in December. Mendus presented encouraging long-term survival data from the ADVANCE II trial investigating vididencel as monotherapy, wh

Newsfile 5 months ago

IMMU.ST
Mendus AB (STU:1YG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Mendus AB (STU:1YG0) reports significant progress in clinical trials and manufacturing alliances, despite a Q3 net loss of 23 million.

GuruFocus.com 7 months ago

1YG0.SG

Performance Overview

Return	1YG0.F	^OMX (^OMX)
YTD	-17.22%	-0.95%
1-Year	-29.12%	-4.93%
3-Year	-87.00%	+25.71%